Tag Archives: clinical decision-making

Managing Type 2 diabetes used to follow a relatively predictable path. Clinicians often started with metformin and added medications gradually as glucose control worsened. Today, however, diabetes care looks very different. The number of available therapies has expanded rapidly, and while that growth has improved patient outcomes, it has also …

What happens when a patient does not fit the textbook definition of diabetes care? In real-world practice, uncertainty in diabetes care is more common than many clinicians expect. While guidelines provide a strong foundation, they cannot cover every clinical scenario. As a result, providers often face complex decisions without clear …

When diabetes metric discordance shows up in clinical practice, it can feel like trying to read three clocks that all tell different times. A1C suggests one story, continuous glucose monitoring points to another, and patient symptoms may not match either. So how should clinicians respond when these signals conflict? Understanding …

Prioritizing diabetes visits has become essential as clinical care grows more complex and time-limited. With new medications, tighter guidelines, and multiple comorbidities, clinicians often feel like they are solving a puzzle against the clock. So how can you make every minute count without sacrificing care quality? This guide breaks down …

Continuous ketone monitoring is gaining attention as a promising tool for detecting metabolic risk earlier than traditional methods. While glucose monitoring has long been the standard, ketones offer another layer of insight into how the body processes energy. Could this emerging technology reshape how clinicians assess risk and guide treatment …

What happens when a once-costly, class-specific treatment becomes a global health priority? That’s the question raised by the World Health Organization’s latest move: recognizing GLP‑1 receptor agonists as essential medicines and issuing new recommendations for their use in obesity and diabetes care. These updated GLP‑1 WHO guidelines are more than …

For decades, metformin has been the backbone of type 2 diabetes therapy. As we move through 2026, the future of metformin in type 2 diabetes treatment is under fresh scrutiny. Should it still be the first-line agent, or have newer drug classes like GLP‑1 receptor agonists and SGLT2 inhibitors earned …